Trial of Penicillamine in Advanced Primary Biliary Cirrhosis

Authors:
  • EDE. Rolland Dickson
    E. Rolland Dickson
  • TFThomas R. Fleming
    Thomas R. Fleming
  • RWRussell H. Wiesner
    Russell H. Wiesner
  • WBWilliam P. Baldus
    William P. Baldus
  • CFC. Richard Fleming
    C. Richard Fleming
  • JLJurgen Ludwig
    Jurgen Ludwig
  • JMJohn T. McCall
    John T. McCall
Publisher website
Google Scholar
Abstract
A total of 227 patients with histologically advanced primary biliary cirrhosis entered a double-blind, randomized, controlled trial to determine whether penicillamine (1 g per day) was therapeutically effective; 111 patients received the drug, and 116 received placebo. The two groups were highly comparable at entry with regard to clinical, biochemical, and histologic features. Penicillamine therapy did not result in an overall improvement in survival as compared with placebo. Clinical symptoms and serial hepatic laboratory values reflected the progressive nature of the disease and were similar in both groups. There were no substantial differences between treatment groups in the morphologic features of sequential biopsy specimens. The development of major side effects led to permanent discontinuation of penicillamine in 22 per cent of the patients taking the drug.

This publication has 9 references indexed in Scilit: